AIR OPTIX® COLORS Registration Trial
Launched by CIBA VISION · Sep 22, 2011
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
This study consisted of 7 scheduled visits conducted over a 3-month period. Enrolled participants were randomized (2:1) to receive either AIR OPTIX® COLORS lenses in both eyes or AIR OPTIX® AQUA lenses in both eyes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Be of legal age of consent and sign Informed Consent document. If under legal age of consent, legally authorized representative must sign Informed Consent document and subject must sign Assent document.
- • Normal eyes and not using any ocular medications.
- • Willing to wear visitint or gray-colored spherical contact lenses in both eyes within available power ranges.
- • Manifest cylinder less than or equal to 0.75 diopter.
- • Best spectacle corrected visual acuity greater than or equal to 20/25.
- • Have current prescription glasses.
- • Other protocol-defined inclusion criteria may apply.
- Exclusion Criteria:
- • Anterior segment infection, inflammation, or abnormality.
- • Any active anterior segment ocular or systemic disease that would contraindicate contact lens wear.
- • Use of ocular or systemic medications for which contact lens wear could be contraindicated as determined by the investigator.
- • History of refractive surgery or irregular cornea.
- • History of pathologically dry eye.
- • Corneal vascularization greater than 1 millimeter of penetration.
- • History of herpetic keratitis.
- • Eye injury within 12 weeks immediately prior to enrollment in this trial.
- • Currently enrolled in any clinical trial or participation in any clinical trial within the previous 30 days.
- • Other protocol-defined exclusion criteria may apply.
About Ciba Vision
Ciba Vision, a global leader in the development and manufacturing of innovative eye care products, specializes in contact lenses and lens care solutions. With a strong commitment to enhancing visual health and improving patient outcomes, Ciba Vision focuses on research and development to deliver cutting-edge technologies and products that meet the evolving needs of eye care professionals and consumers. The company is dedicated to advancing clinical trials that explore new therapies and solutions in ophthalmology, ensuring the highest standards of safety and efficacy in its offerings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Sharon Holden Thomas, OD
Study Director
Alcon Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials